Akari Therapeutics (United Kingdom)

Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease

Tanya Sezin, Sripriya Murthy, Claudia Attah et al. · JCI Insight · 2019 · 48 citations · Full text

Life Sciences, Dermatology, Immunology +17

Use of the complement inhibitor Coversin to treat HSCT-associated TMA

Timothy H.J. Goodship, Fernando Pinto, Wynn H. Weston-Davies et al. · Blood Advances · 2017 · 45 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function

Alice Gustavsen, Hilde L. Orrem, K. Egge et al. · Basic Research in Cardiology · 2017 · 40 citations · Full text

Medicine, Cardiology, Pharmacology +17

Evaluation of Nomacopan for Treatment of Bullous Pemphigoid

Christian D. Sadik, Hanan Rashid, Christoph M. Hammers et al. · JAMA Dermatology · 2022 · 38 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Successful treatment of a PNH patient non‐responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)

Saskia E.M. Schols, Miles A. Nunn, Ian Mackie et al. · British Journal of Haematology · 2019 · 32 citations · Full text

Medicine, Hematology, Pharmacology +16